Navigation Links
First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
Date:1/13/2009

SAN CARLOS, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that dosing has started in a Phase 2 clinical trial of NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals have also been obtained and dosing will begin shortly in two additional trials: a randomized Phase 2 study to evaluate NKTR-102 versus irinotecan in second-line colorectal cancer patients with the KRAS gene mutation, and a Phase 2 study in metastatic breast cancer. Nektar has also received Institutional Review Board (IRB) approval for a Phase 2 cervical cancer study of NKTR-102.

"NKTR-102 is an excellent example of how Nektar's advanced polymer conjugate technology platform allowed us to precisely modify a cytotoxic agent with sub-optimal pharmacokinetics and enhance its therapeutic profile," said Randall Moreadith, M.D., Ph.D., Senior Vice President and Chief Development Officer of Nektar. "We are excited to have dosed our first patient in the start of our expanded Phase 2 clinical development program. NKTR-102 is a novel oncolytic that has the potential to dramatically expand therapeutic options for oncologists and improve survival rates for patients with a variety of cancers."

Using its proprietary polymer conjugate technology platform, Nektar is the first company to have created a small molecule PEGylated drug conjugate that has demonstrated therapeutic activity in patients. In addition to the Phase 2 clinical studies in breast, ovarian, cervical and colorectal cancers, a Phase 2a study evaluating NKTR-102 in combination with cetuximab has completed enrollment and full results of this study are expected to be available in the first half of 2009.

About the NKTR-102 Phase 2 Study Designs

The NKTR-102 Phase 2 randomized trial will evaluate the efficacy
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 2009 Marks 50 Years of Innovative Firsts for Instrumentation Laboratory
2. Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase
3. The IN VIVO Blog Selects First Annual Deal of the Year
4. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
5. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
6. First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform
7. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
8. USC researchers derive first embryonic stem cells from rats
9. ASP Announces Availability of EVOTECH(TM) Endoscope Cleaner and Reprocessor - First Commercially Available System to Eliminate Manual Cleaning of Endoscopes
10. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
11. Bioamber announces worlds first bio-based succinic acid plant: helping to reduce dependence on fossil fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/20/2014)... Clintrax Global, Inc., a worldwide provider ... Raleigh, NC , recently announced the addition ... of Administration. As Vice President ... including their alignment with company objectives and policies.  ... an HR executive, specializing in needs assessments, customer ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 2
... , ... , , , ... samples of low cell numbers , , , ... cells have, for example,limited availability, quantity,and lifespan. Using the Agilent,2100 bioanalyzer ...
... , , , ... , , , , ... Agilent 2100 bioanalyzer can,be used to analyze apoptotic cell samples. Performance ... compared to,those obtained with a conventional flow cytometer. Histogram quality,of the ...
... , , , , ... The In Situ Cell Death Detection Kit has been designed as a precise, fast, and simple, ... the single-cell level in tissues. It is based on the so-called TUNEL, ... , , , , ...
Cached Biology Technology:Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 2Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 2Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 4Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 5Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 6Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 7Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 8Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 9In Situ Cell Death Detection Kit 2
(Date:8/20/2014)... University of Tennessee, Knoxville, research finds life can persist ... professor was part of a team that examined waters ... Antarctic ice sheet and found the extreme environment supports ... by Jill Mikucki and her colleagues has implications for ... in the solar system. The findings are published in ...
(Date:8/20/2014)... MA Using population-based screening outcomes of approximately 3 ... including four researchers at the University of Massachusetts Medical ... immunodeficiency (SCID) can be successfully implemented across public health ... published in the Aug. 20 issue of the ... ) showed the rate of SCID in newborns is ...
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... bioMETRX, Inc., (OTC,Bulletin Board: BMRX), the leading ... that Frank Santamorena, a world,renowned security expert, ... October 21, 2008., Frank Santamorena brings ... level,security expertise. Frank is a consultant to ...
... A UC Davis researcher known for her honey ... with their Old World counterparts to enhance their positive ... and very productive, and hopefully will confer increased resistance ... Susan Cobey. The Carniolan honey bee ( Apis ...
... From stiff plastic limbs and metal rods to complex ... test dummies of yesteryear are evolving and researchers at Wake ... to life. This new generation of human body ... known in research "dummies" before. The models will contain detailed ...
Cached Biology News:bioMETRX, Inc. Welcomes Residential and Commercial Security Expert to Board of Directors 2bioMETRX, Inc. Welcomes Residential and Commercial Security Expert to Board of Directors 3Building a better bee 2Wake Forest plays integral role in effort to revolutionize vehicle safety 2Wake Forest plays integral role in effort to revolutionize vehicle safety 3
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: